| Pemetrexed | lung cancer (metastatic), in all type of patients | vs docetaxel | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| objective response (ORR) | no data | | death (overall survival) | no data | | progression or death (progression free survival PFS) | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| Chen, 2008 | | | | | Hanna, 2004 | pemetrexed 500 mg/m(2) intravenously (i.v.) day 1 with vitamin B(12), folic acid, and dexamethasone | docetaxel 75 mg/m(2) i.v. day 1 with dexamethasone every 21 days | patients with advanced non-small-cell lung cancer (NSCLC) previously treated with chemotherapy | | Li, 2012 | pemetrexed 500 mg/m(2) intravenously day 1 with vitamin B12, folic acid, and dexamethasone | docetaxel 75 mg/m(2) intravenously day 1 with dexamethasone | patients with histological or cytological diagnosis of stage IIIB or IV NSCLC, who were not suitable for curative therapy and had failed from prior first line chemotherapy regimen for at least 4 weeks | | Sun, 2013 | pemetrexed (500 mg/m(2); on Day 1 of each 21-day cycle | docetaxel (75 mg/m(2) on Day 1 of each 21-day cycle | second-line therapy for Chinese patients with locally advanced or metastatic non-small cell lung cancer |
| |
| Pemetrexed | | vs docetaxel plus carboplatin | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| objective response (ORR) | no data | | death (overall survival) | no data | | progression or death (progression free survival PFS) | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| Jose, 2011 | carboplatin (area under the curve = 5 mg/ml × min) and pemetrexed (500 mg/m(2)) 21-day cycle (maximum of six cycles). | docetaxel (75 mg/m(2)). | first-line treatment for advanced, nonsquamous non-small cell lung cancer | | Socinski, 2010 | pemetrexed 500 mg/m and carboplatin area under the curve 6 once every 3 weeks for up to 6 cycles | docetaxel 75 mg/m and carboplatin area under the curve 6 once every 3 weeks for up to six cycles | Patients with stage IIIB (with pleural effusion) or IV non-small cell lung cancer and performance status 0 or 1 |
| |
| Pemetrexed | | vs pemetrexed | objective response (ORR) by 191% suggested progression or death (progression free survival PFS) by 33% suggested | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| objective response (ORR) | 2.91 [1.18 7.15] | p=0.04 | 0 | -18 | 1 | Smit, | | death (overall survival) | 0.85 [0.62 1.17] | p=1.00 | 0 | -18 | 1 | Smit, | | progression or death (progression free survival PFS) | 0.67 [0.51 0.89] | p=0.04 | 0 | -18 | 1 | Smit, |
| Trial | Studied treatment | Control | Patients |
|---|
| Smit, 2009 | Pemetrexed plus carboplatin | pemetrexed | |
| |
| Vandetanib | lung cancer (metastatic), in all type of patients | vs pemetrexed | objective response (ORR) by 142% suggested | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| objective response (ORR) | 2.42 [1.42 4.12] | p=0.04 | 0 | -18 | 1 | De Boer, | | death (overall survival) | 0.89 [0.73 1.09] | p=1.00 | 0 | -18 | 1 | De Boer, | | progression or death (progression free survival PFS) | 0.83 [0.68 1.01] | p=1.00 | 0 | -18 | 1 | De Boer, |
| Trial | Studied treatment | Control | Patients |
|---|
| De Boer, 2011 | Vandetanib plus pemetrexed | pemetrexed | |
| |
